AIM: Different strains of bifidobacteria were analysed for their effects on HT-29 intestinal epithelial cells (IECs) in in vitro models both of the non-inflamed and inflamed intestinal epithelium. METHODS: A reporter gene system in HT-29 cells was used to measure levels of NF-kappaB activation after challenge with bifidobacteria or after bacterial pre-treatment following LPS challenge. IL-8 protein and pro-inflammatory gene expression was investigated using normal HT-29 cells. RESULTS: None of the bifidobacteria tested induced activation of nuclear factor kappaB (NF-kappaB) indicating that bifidobacteria themselves do not induce inflammatory events in IECs. However, six out of eight bifidobacteria tested inhibited lipopolysaccharide- (LPS-) induced NF-kappaB activation in a dose- and strain-dependent manner. In contrast, NF-kappaB activation in response to challenge with tumor necrosis factor-alpha (TNF-alpha) was affected by none of the tested bifidobacteria, indicating that the inhibitory effect of bifidobacteria is specific for LPS-induced inflammation in IECs. As shown with two of the six inhibition-positive bifidobacteria, LPS-induced inhibition of NF-kappaB activation was accompanied by a dose-dependent decrease of interleukin 8 (IL-8) secretion and by lower mRNA levels for IL-8, TNF-alpha, cyclooxygenase 2 (Cox-2), and intercellular adhesion molecule 1 (ICAM-1). CONCLUSION: Some strains of bifidobacteria are effective in inhibiting LPS-induced inflammation and thus might be appropriate candidates for probiotic intervention in chronic intestinal inflammation.
AIM: Different strains of bifidobacteria were analysed for their effects on HT-29 intestinal epithelial cells (IECs) in in vitro models both of the non-inflamed and inflamed intestinal epithelium. METHODS: A reporter gene system in HT-29 cells was used to measure levels of NF-kappaB activation after challenge with bifidobacteria or after bacterial pre-treatment following LPS challenge. IL-8 protein and pro-inflammatory gene expression was investigated using normal HT-29 cells. RESULTS: None of the bifidobacteria tested induced activation of nuclear factor kappaB (NF-kappaB) indicating that bifidobacteria themselves do not induce inflammatory events in IECs. However, six out of eight bifidobacteria tested inhibited lipopolysaccharide- (LPS-) induced NF-kappaB activation in a dose- and strain-dependent manner. In contrast, NF-kappaB activation in response to challenge with tumor necrosis factor-alpha (TNF-alpha) was affected by none of the tested bifidobacteria, indicating that the inhibitory effect of bifidobacteria is specific for LPS-induced inflammation in IECs. As shown with two of the six inhibition-positive bifidobacteria, LPS-induced inhibition of NF-kappaB activation was accompanied by a dose-dependent decrease of interleukin 8 (IL-8) secretion and by lower mRNA levels for IL-8, TNF-alpha, cyclooxygenase 2 (Cox-2), and intercellular adhesion molecule 1 (ICAM-1). CONCLUSION: Some strains of bifidobacteria are effective in inhibiting LPS-induced inflammation and thus might be appropriate candidates for probiotic intervention in chronic intestinal inflammation.
Authors: H J Harmsen; A C Wildeboer-Veloo; G C Raangs; A A Wagendorp; N Klijn; J G Bindels; G W Welling Journal: J Pediatr Gastroenterol Nutr Date: 2000-01 Impact factor: 2.839
Authors: P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri Journal: Gastroenterology Date: 2000-08 Impact factor: 22.682
Authors: N V Contractor; H Bassiri; T Reya; A Y Park; D C Baumgart; M A Wasik; S G Emerson; S R Carding Journal: J Immunol Date: 1998-01-01 Impact factor: 5.422
Authors: R K Sellon; S Tonkonogy; M Schultz; L A Dieleman; W Grenther; E Balish; D M Rennick; R B Sartor Journal: Infect Immun Date: 1998-11 Impact factor: 3.441
Authors: M O Labéta; K Vidal; J E Nores; M Arias; N Vita; B P Morgan; J C Guillemot; D Loyaux; P Ferrara; D Schmid; M Affolter; L K Borysiewicz; A Donnet-Hughes; E J Schiffrin Journal: J Exp Med Date: 2000-05-15 Impact factor: 14.307
Authors: Daria Zhurina; Aldert Zomer; Marita Gleinser; Vincenco Francesco Brancaccio; Marc Auchter; Mark S Waidmann; Christina Westermann; Douwe van Sinderen; Christian U Riedel Journal: J Bacteriol Date: 2010-10-29 Impact factor: 3.490
Authors: Julia Preising; David Philippe; Marita Gleinser; Hua Wei; Stephanie Blum; Bernhard J Eikmanns; Jan-Hendrik Niess; Christian U Riedel Journal: Appl Environ Microbiol Date: 2010-03-12 Impact factor: 4.792
Authors: Mark A Underwood; Nita H Salzman; Stephen H Bennett; Melissa Barman; David A Mills; Angela Marcobal; Daniel J Tancredi; Charles L Bevins; Michael P Sherman Journal: J Pediatr Gastroenterol Nutr Date: 2009-02 Impact factor: 2.839